Drug Profile
ASP 2535
Alternative Names: ASP2535Latest Information Update: 17 Jun 2009
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Class Antidementias; Antipsychotics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease; Schizophrenia
Most Recent Events
- 29 May 2009 Discontinued - Phase-I for Alzheimer's disease in Japan (PO)
- 29 May 2009 Discontinued - Phase-I for Schizophrenia in Japan (PO)
- 29 Aug 2008 Phase-I clinical trials in Alzheimer's disease in Japan (PO)